Please login to the form below

Not currently logged in
Email:
Password:

Enterprise Therapeutics appoints CEO

Dr John Ford will lead the UK drug discovery company

Enterprise Therapeutics Dr John FordBrighton, UK-based respiratory diseases specialist Enterprise Therapeutics has appointed Dr John Ford as chief executive officer, with immediate effect.

In his new role, Dr Ford will oversee the development of the company's novel muco-regulatory therapies for patients suffering with chronic obstructive pulmonary disease, cystic fibrosis and severe asthma.

He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

Dr Ford also brings experience from Ario Pharma, where he is currently chief executive officer and co-founder, and Metrion Biosciences, where he serves as co-owner and investor director.

Previously, Dr Ford has worked as general manager of Akarna Therapeutics' UK operations, chief operating officer of Dezima Pharma and a team leader for cell-based drug discovery campaigns at BioFocus Discovery.

Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels, drug development, and biotech fundraising position him uniquely to lead Enterprise Therapeutics moving forward.

“His expertise will complement the existing team and we are thrilled to have him on board.”

3rd November 2016

From: Sales

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...